Frontiers in Pharmacology
Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes
Study in peopleInterventions
Papers by Jheng-Yan Wu
13 results
- Drug Design, Development and Therapy
Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study
Cohort study of 11,969 peopleSepsis - Frontiers in Pharmacology
SGLT2 inhibitors and outcomes in the chronic Post-LVAD phase: a multicenter real-world cohort study
Cohort study in peopleSGLT2 inhibitors - Nature Communications
Glucagon-like Peptide-1 Receptor Agonists and Risk of Tuberculosis in Type 2 Diabetes
Study in peoplePopulations
- Diabetes, Obesity & Metabolism
Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity
Cohort study of 9,222 peopleGLP-1 receptor agonists - JACC Advances
PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease
Study in peopleInterventions - QJM
Association Between PCSK9 Inhibitor Use and Risk of Incident Heart Failure in Patients With Dyslipidemia
Cohort study of 40,098 peoplePCSK9 inhibitors - Frontiers in Endocrinology
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Cohort study of 30,292 peopleTirzepatide - Frontiers in Urology
Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy
Cohort study of 1,009 peopleGLP-1 receptor agonists - Frontiers in Pharmacology
Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study
Cohort study of 189,156 peopleCardiomyopathy - Frontiers in Nutrition
Serum zinc deficiency and progression of cardiovascular- kidney-metabolic syndrome
Study in peoplePopulations